GSK (GSK) said it is “pleased” that the Advisory Committee on Immunization Practices voted in favor of recommending the use of RSV vaccines ...

Goldman Sachs says the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices published its final agenda ...

Goldman Sachs said Monday that GSK (NYSE:GSK) is set for a 'positive surprise' this week as a CDC Advisory Committee is scheduled to discuss whether to broaden the recommendation for Arexvy ...

The massive trial saw 24,972 people aged 60 or older get either the RSVPreF3 OA vaccine (brand name Arexvy, by GSK) or a placebo, administered in 275 clinics across 17 countries across five ...

Vaccine makers targeting COVID-19 to measles will come under investor scrutiny on Tuesday as a group of independent experts at the CDC are scheduled to meet for the first time to review U.S ...

It is still very early days, but GSK’s respiratory syncytial virus (RSV) Arexvy seems to have flown out of the traps more quickly than Pfizer’s rival shot Abrysvo in the first weeks since they ...

The FDA has approved GSK’s Arexvy shot for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years of age and older, shortly after it was recommended for approval ...

Chairman & CEO. “Faisal has a proven track record in integrating cutting-edge science with practical, evidence-base PHILADELPHIA, October 24, 2024--New data for AREXVY, GSK’s RSV vaccine ...

An all-encompassing guide to understanding vaccines. Vaccines aren't just for kids; adults also need them to guard against serious diseases. Discover the essential vaccine schedule to stay healthy ...

vaccine Abrysvo violated GSK's patent rights in its competing RSV shot Arexvy, according to a Thursday filing in Delaware federal court. Drugmaker stocks gained a temporary reprieve on Thursday as ...